Oncology: EMEA Approval Lags

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-10-01-2001
Volume 0
Issue 0

London-European cancer patients are losing out because current processes for reviewing treatments are "dire," says the Cancer Research Campaign.

Related Videos
Related Content